{"entity":{"id":"nct03812874","kind":"trial","name":"A Study of PTX-9908 Injection for Non-resectable HCC with TACE","aka":[],"tldr":"A phase 1/2 trial of PTX-9908 Injection in hepatocellular carcinoma, run by TCM Biotech International Corp., now recruiting.","summary":"A Study of PTX-9908 Injection for Non-resectable HCC with TACE is a phase 1/2 interventional study registered as NCT03812874 by TCM Biotech International Corp., with 50 participants planned, started 2020-10-06 and due to reach its primary completion in 2026-08-30. Interventions recorded: PTX-9908 Injection and Placebo.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT03812874","url":"https://clinicaltrials.gov/study/NCT03812874"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["hcc","hcc-intermediate"],"sections":[],"technologies":["tace"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03812874","phase":"1/2","setting":"Phase I/II Study of PTX-9908 Injection As an Inhibitor of Cancer Progression in Patients with Non-resectable Hepatocellular Carcinoma Following Transarterial Chemoembolization Treatment","sponsor":"TCM Biotech International Corp.","started":"2020-10-06","startedType":"actual","enrolled":50,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct03812874/","neighbours":{"cancer":[{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"},{"id":"hcc-intermediate","kind":"cancer","name":"Intermediate hepatocellular carcinoma (BCLC B)","route":"/cancers/hcc-intermediate/"}],"technology":[{"id":"tace","kind":"technology","name":"Transarterial chemoembolisation (TACE)","route":"/technologies/tace/"}]}}